載入...
KRAS G12C Mutations in NSCLC: From Target to Resistance
SIMPLE SUMMARY: A better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer. While these therapies hold grea...
Na minha lista:
| 發表在: | Cancers (Basel) |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8196854/ https://ncbi.nlm.nih.gov/pubmed/34064232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112541 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|